- Home
- OPAD vs TNXP Comparison
OPAD vs TNXP Comparison
Compare OPAD & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPAD
- TNXP
- Stock Information
- Founded
- OPAD 2015
- TNXP 2007
- Country
- OPAD United States
- TNXP United States
- Employees
- OPAD N/A
- TNXP N/A
- Industry
- OPAD Real Estate
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- OPAD Finance
- TNXP Health Care
- Exchange
- OPAD Nasdaq
- TNXP Nasdaq
- Market Cap
- OPAD 70.1M
- TNXP 57.9M
- IPO Year
- OPAD N/A
- TNXP N/A
- Fundamental
- Price
- OPAD $2.75
- TNXP $0.24
- Analyst Decision
- OPAD Hold
- TNXP Strong Buy
- Analyst Count
- OPAD 6
- TNXP 2
- Target Price
- OPAD $5.19
- TNXP $53.50
- AVG Volume (30 Days)
- OPAD 62.4K
- TNXP 134.8M
- Earning Date
- OPAD 02-24-2025
- TNXP 11-12-2024
- Dividend Yield
- OPAD N/A
- TNXP N/A
- EPS Growth
- OPAD N/A
- TNXP N/A
- EPS
- OPAD N/A
- TNXP N/A
- Revenue
- OPAD $985,005,000.00
- TNXP $11,291,000.00
- Revenue This Year
- OPAD N/A
- TNXP $64.71
- Revenue Next Year
- OPAD $37.39
- TNXP $24.49
- P/E Ratio
- OPAD N/A
- TNXP N/A
- Revenue Growth
- OPAD N/A
- TNXP 183.05
- 52 Week Low
- OPAD $2.25
- TNXP $0.12
- 52 Week High
- OPAD $9.93
- TNXP $12.48
- Technical
- Relative Strength Index (RSI)
- OPAD 41.89
- TNXP 43.95
- Support Level
- OPAD $2.25
- TNXP $0.22
- Resistance Level
- OPAD $3.17
- TNXP $0.26
- Average True Range (ATR)
- OPAD 0.30
- TNXP 0.04
- MACD
- OPAD 0.03
- TNXP -0.02
- Stochastic Oscillator
- OPAD 42.92
- TNXP 7.38
About OPAD Offerpad Solutions Inc.
Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services including mortgage, listing, renovation and buyer representation services.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.